Immunocore Announces First Patient Dosed in Phase 1 Trial of Half-Life Extended ImmTAC Candidate
Dec. 23, 2024
Immunocore has initiated a Phase 1 trial for IMC-P115C (PRAME-HLE-A02), its first half-life extended ImmTAC candidate designed to enhance patient convenience by reducing treatment frequency. IMC-P115C, a PRAME x CD3 ImmTAC bispecific protein, builds on the extensive Phase 1/2 PRAME data set from brenetafusp, which informed the first Phase 3 trial with a PRAME therapy. The trial will assess the safety, pharmacokinetics, and clinical activity of IMC-P115C in patients with advanced PRAME-expressing cancers.
Full Article: Immunocore Announces First Patient Dosed in Phase 1 Trial of Half-Life Extended ImmTAC Candidate
Syncromune Raises $100M in Series A for Cancer Therapies
Dec. 23, 2024
Syncromune, a biotech startup focused on developing first-in-class immunotherapies for solid tumors, has raised a $100 million Series A round, bringing its total funding to $130 million. The funds will support the Phase 2a trial of its drug candidate SV-102 for metastatic castration-resistant prostate cancer. Syncromune’s innovative approach combines tumor freezing with multiple immunotherapies to stimulate the patient’s immune response, addressing the unmet needs of metastatic solid tumor cancers. Led by CEO Eamonn Hobbs, the company is advancing therapies for metastatic lung, breast, and prostate cancers.
Full Article: Syncromune Raises $100M for Cancer Therapies
Radiopharm Theranostics Receives Approval to Initiate Phase 1 Trial of Radiopharmaceutical for HER2-Positive Tumors
Dec. 24, 2024
Radiopharm Theranostics has received Human Research Ethics Committee (HREC) approval in Australia to initiate a Phase 1 first-in-human (FIH) trial of 177Lu-RAD202, a radiopharmaceutical targeting HER2-positive metastatic solid tumors. The open-label HEAT trial will assess safety, tolerability, and preliminary clinical activity. RAD 202, a single-domain monoclonal antibody, has shown promising safety, biodistribution, and preclinical efficacy in HER2-expressing cancers. CEO Riccardo Canevari expressed optimism about its potential to address unmet treatment gaps in refractory HER2-positive cancers.
Full Article: Radiopharm Theranostics Receives Approval to Initiate Phase 1 Trial
RadioNano Therapeutics Raises ¥600M in Series A Funding for Cancer Treatment Development
Dec. 25, 2024
RadioNano Therapeutics, a spinoff from Kyoto University, has raised ¥600 million in Series A funding to advance its nanoparticle-based therapy, RN-501, for Boron Neutron Capture Therapy (BNCT) in cancer treatment. The funding will support the development of RN-501, which shows promising tumor selectivity and strong anti-cancer effects.
Full Article: RadioNano Therapeutics Raises ¥600M for BNCT Development
Tolerance Bio Secures $20.2M in Seed Funding to Advance Immune Tolerance Therapies
Dec. 27, 2024
Tolerance Bio has secured $20.2 million in seed funding to accelerate the development of its thymus cell therapy platform and allogeneic iPSC-based treatments for immune-mediated diseases. The company aims to address cancer and autoimmunity using innovative immune tolerance and regenerative medicine strategies.
Full Article: Tolerance Bio Secures $20.2M Seed Funding
